RxDoctor Payments Data

Roy Springer

Family Medicine · San Diego, CANPI 1942497318

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Novo Nordisk at 56.2% of the total.

$308in general payments, 2019–2025

Across 29 payments — averaging $10.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$173
  • Organogenesis Inc.$87
  • Avanir Pharmaceuticals, Inc.$20
  • Merck$15
  • Sanofi-aventis U.S. LLC$14
$532,963in research payments, 2019–2025

Across 125 payments — averaging $4263.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • LEO Pharma AS$188K
  • Kowa Research Institute, Inc.$182K
  • AbbVie$78K
  • Genentech, Inc.$67K
  • AstraZeneca$18K

What the payments were for

  • Food & beverage$308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$308 in reported general payments places this provider in the 55th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Other family medicine in San Diego

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →